Table 2 Multivariate analysis.

	Cumulative incidence of relapse		Event-free survival		Overall survival
	HR*	P	HR*	P	HR* (95% CI)	P
ELN2022 risk (adverse vs intermediate vs favorable)	1.91 (1.45–2.52)	<0.001	1.59 (1.27–1.97)	<0.001	1.32 (1.03–1.70)	0.03
MRD status at HSCT (MRD^pos vs MRD^neg)	3.81 (2.42–6.00)	<0.001	2.43 (1.70–3.46)	<0.001	1.70 (1.13–2.56)	0.01
Conditioning intensity (MAC vs RIC/NMA)	-	-	-	-	0.56 (0.38–0.86)	0.007
Number of remission at HSCT (no remission vs second vs first)	2.48 (1.63–3.78)	<0.001	1.60 (1.10–2.34)	0.01	-

Variables considered in the models were those significant at α = 0.10 in univariate analyses.
For CIR endpoint, variables considered were: ELN2022 risk group, conditioning regimen (RIC/NMA vs MAC), pre-HSCT MRD status (MRD^pos vs MRD^neg), and the number of remission at HSCT (no remission vs second vs first). For the EFS endpoint, variables considered were: age at HSCT (≥60 vs <60 years), ELN2022 genetic risk group, disease origin (de novo vs secondary/treatment-related), pre-HSCT MRD status (MRD^pos vs MRD^neg), conditioning regimen (RIC/NMA vs MAC), and the number of remission at HSCT (no remission vs second vs first). For the OS endpoint, variables considered were: age at HSCT (≥60 vs <60 years), disease origin (de novo vs secondary/treatment-related), ELN2022 genetic risk group, pre-HSCT MRD status (MRD^pos vs MRD^neg), conditioning regimen (RIC/NMA vs MAC), and the number of remission at HSCT (no remission vs second vs first).
CI confidence interval, ELN2022 European LeukemiaNet 2022, HSCT hematopoietic stem cell transplantation, MAC myeloablative conditioning, MRD measurable residual disease, NMA non-myeloablative conditioning, RIC reduced-intensity conditioning.
*HR hazard ratio, <1 (>1) indicates a lower (higher) risk of relapse for the first category listed for the dichotomous variables for the lower (higher) values of the continuous variables.

Search